Mechanisms of Action of Antiepileptic Drugs

International Review of Neurobiology

Volumn 81, Issue , 2007, Pages 85-110

  White, H Steve ^a   Smith, Misty D ^a   Wilcox, Karen S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ION CHANNEL;

ANIMAL; CLASSIFICATION; ELECTROPHYSIOLOGY; EPILEPSY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTICONVULSANTS; ELECTROPHYSIOLOGY; EPILEPSY; HUMANS; ION CHANNELS;

EID: 34047204206     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(06)81006-8     Document Type: Review

References (162)

1. Adusumalli V.E., Wichmann J.K., Kucharczyk N., and Sofia R.D. Distribution of the anticonvulsant felbamate to cerebrospinal fluid and brain tissue of adult and neonatal rats. Drug Metab. Dispos. 21 (1993) 1079-1085
2. Adusumalli V.E., Wichmann J.K., Kucharczyk N., Kamin M., Sofia R.D., French J., Sperling M., Bourgeois B., Devinsky O., Dreifuss F.E., Kuzniecky R.I., Faught E., et al. Drug concentrations in human brain tissue samples from epileptic patients treated with felbamate. Drug Metab. Dispos. 22 (1994) 168-170
3. Bertrand S., Ng G.Y., Purisai M.G., Wolfe S.E., Severidt M.W., Nouel D., Robitaille R., Low M.J., O'Neill G.P., Metters K., Lacaille J.C., Chronwall B.M., et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J. Pharmacol. Exp. Ther. 298 (2001) 15-24
4. Birnstiel S., Wulfert E., and Beck S.G. Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 611-618
5. Braestrup C., Nielsen E.B., Sonnewald U., Knutsen L.J., Andersen K.E., Jansen J.A., Frederiksen K., Andersen P.H., Mortensen A., and Suzdak P.D. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J. Neurochem. 54 (1990) 639-647
6. Calabresi P., De Murtas M., Stefani A., Pisani A., Sancesario G., Mercuri N.B., and Bernardi G. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 (1995) 990-996
7. Capek R., and Esplin B. Effects of valproate on action potentials and repetitive firing of CA1 pyramidal cells in the hippocampal slice preparation. Soc. Neurosci. Abstr. 12 (1986) 46 Abstract 17.19
8. Cheung H., Kamp D., and Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 13 (1992) 107-112
9. Coffin V., Cohen-Williams M., and Barnett A. Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur. J. Pharmacol. 256 (1994) R9-R10
10. Coulter D.A. Antiepileptic drug cellular mechanisms of action: Where does lamotrigine fit in?. J. Child Neurol. 12 Suppl. 1 (1997) S2-S9
11. Coulter D.A., Huguenard J.R., and Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol. 25 (1989) 582-593
12. Coulter D.A., Sombati S., and DeLorenzo R.J. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 34 Suppl. 2 (1983) 123
13. Dam M., and Ostergaard L.H. Other antiepileptic drugs. Oxcarbazepine. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). "Antiepileptic Drugs". 4th ed. (1995), Raven Press Ltd., New York 987-995
14. Dam M., Ekberg R., Loyning Y., Waltimo O., and Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3 (1989) 70-76
15. DeLorenzo R.J., and Sun D.A. Phenytoin and other hydantoins: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 551-564
16. DeLorenzo R.J., Sombati S., and Coulter D.A. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41 Suppl. 1 (2000) S40-S44
17. De Sarro G., Ongini E., Bertorelli R., Aguglia U., and De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur. J. Pharmacol. 262 (1994) 11-19
18. De Smedt T., Vonck K., Raedt R., Dedeurwaerdere S., Claeys P., Legros B., Wyckhuys T., Wadman W., and Boon P. Rapid kindling in preclinical anti-epileptic drug development: The effect of levetiracetam. Epilepsy Res. 67 (2005) 109-116
19. Dichter M.A., and Ayala G.F. Cellular mechanisms of epilepsy: A status report. Science 237 (1987) 157-164
20. Dildy-Mayfield J.E., Eger II E.I., and Harris R.A. Anesthetics produce subunit-selective actions on glutamate receptors. J. Pharmacol. Exp. Ther. 276 (1996) 1058-1065
21. Dodgson S.J., Shank R.P., and Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 Suppl. 1 (2000) S35-S39
22. During M., Mattson R., Scheyer R., Rask C., Pierce M., McKelvy J., and Thomas V. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus [abstract]. Epilepsia 33 Suppl. 3 (1992) 83
23. Fink-Jensen A., Suzdak P.D., Swedberg M.D., Judge M.E., Hansen L., and Nielsen P.G. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. 220 (1992) 197-201
24. Gee N.S., Brown J.P., Dissanayake V.U., Offord J., Thurlow R., and Woodruff G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J. Biol. Chem. 271 (1996) 5768-5776
25. Giardina W.J. Tiagabine: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 675-680
26. Gibbs III J.W., Sombati S., DeLorenzo R.J., and Coulter D.A. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 Suppl. 1 (2000) S10-S16
27. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. ucb L059, a novel anti-convulsant drug: Pharmacological profile in animals. Eur. J. Pharmacol. 222 (1992) 193-203
28. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22 (1995) 207-213
29. Gram L., and Philbert A. Oxcarbazepine. In: Meldrum B.S., and Porter R.J. (Eds). "New Anticonvulsant Drugs" (1986), John Libbey & Co., London 229-235
30. Guerrini R., and Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin. Pharmacother. 7 (2006) 811-823
31. Harty T.P., and Rogawski M.A. Felbamate block of recombinant N-methyl-D-aspartate receptors: Selectivity for the NR2B subunit. Epilepsy Res. 39 (2000) 47-55
32. Herrero A.I., Del Olmo N., Gonzalez-Escalada J.R., and Solis J.M. Two new actions of topiramate: Inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42 (2002) 210-220
33. Holland K.D., and Ferrendelli J.A. Succinimides: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 639-645
34. Hommes O.R., and Obbens E.A. The epileptogenic action of Na-folate in the rat. J. Neurol. Sci. 16 (1972) 271-281
35. Honmou O., Kocsis J.D., and Richerson G.B. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. 20 (1995) 193-202
36. Houtkooper M.A., Lammertsma A., Meyer J.W., Goedhart D.M., Meinardi H., van Oorschot C.A., Blom G.F., Hoppener R.J., and Hulsman J.A. Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine?. Epilepsia 28 (1987) 693-698
37. Jensen P.K., Gram L., and Schmutz M. Oxcarbazepine. Epilepsy Res. Suppl. 3 (1991) 135-140
38. Kelly K.M., Gross R.A., and Macdonald R.L. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci. Lett. 116 (1990) 233-238
39. Kito M., Maehara M., and Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5 (1996) 115-119
40. Kocsis J.D., and Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci. Lett. 169 (1994) 181-184
41. - current at the gamma-aminobutyric AcidA (GABAA) receptor. J. Pharmacol. Exp. Ther. 277 (1996) 1784-1792
42. Kuzmiski J.B., Barr W., Zamponi G.W., and MacVicar B.A. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 46 (2005) 481-489
43. Lang D.G., Wang C.M., and Cooper B.R. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J. Pharmacol. Exp. Ther. 266 (1993) 829-835
44. Leach M.J., Marden C.M., and Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27 (1986) 490-497
45. Leach M.J., Randall A.D., Stefani A., and Hainsworth A.H. Lamotrigine: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed (2002), Lippincott Williams & Wilkins, Philadelphia 363-369
46. Lees G., and Leach M.J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 612 (1993) 190-199
47. Leppik I.E., Kelly K.M., deToledo-Morrell L., Patrylo P.R., DeLorenzo R.J., Mathern G.W., and White H.S. Basic research in epilepsy and aging. Epilepsy Res. 68 Suppl. 1 (2006) S21-S37
48. Leresche N., Parri H.R., Erdemli G., Guyon A., Turner J.P., Williams S.R., Asprodini E., and Crunelli V. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J. Neurosci. 18 (1998) 4842-4853
49. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem. Pharmacol. 30 (1981) 1364-1366
50. Loscher W. Valproic acid: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 767-779
51. Loscher W., Honack D., and Taylor C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci. Lett. 128 (1991) 150-154
52. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA 101 (2004) 9861-9866
53. Macdonald R.L. Antiepileptic drug actions. Epilepsia 30 Suppl. 1 (1989) S19-S28 discussion S64-S68
54. Macdonald R.L. Benzodiazepines: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 179-186
55. Macdonald R.L. Carbamazepine: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 227-235
56. Macdonald R.L. Zonisamide: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 867-872
57. Macdonald R.L., and Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 36 Suppl. 2 (1995) S2-S12
58. Macdonald R.L., and Olsen R.W. GABAA receptor channels. Annu. Rev. Neurosci. 17 (1994) 569-602
59. Macdonald R.L., Rogers C.J., and Twyman R.E. Barbiturate regulation of kinetic properties of the GABAA receptor channel of mouse spinal neurones in culture. J. Physiol. 417 (1989) 483-500
60. Margineanu D.G., and Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. 42 (2000) 281-285
61. Margineanu D.G., and Klitgaard H. Levetiracetam: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 419-427
62. Margineanu D.G., and Wulfert E. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur. J. Pharmacol. 286 (1995) 321-325
63. Margineanu D.G., and Wulfert E. Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. 122 (1997) 1146-1150
64. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., Williamson P.D., Treiman D.M., McNamara J.O., McCutchen C.B., et al. Com- parison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 313 (1985) 145-151
65. McCabe R.T., Wasterlain C.G., Kucharczyk N., Sofia R.D., and Vogel J.R. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J. Pharmacol. Exp. Ther. 264 (1993) 1248-1252
66. McLean M.J. Oxcarbazepine: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 451-458
67. McLean M.J., and Macdonald R.L. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 238 (1986) 727-738
68. McLean M.J., and Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237 (1986) 1001-1011
69. McLean M.J., Schmutz M., Wamil A.W., Olpe H.R., Portet C., and Feldmann K.F. Oxcarbazepine: Mechanisms of action. Epilepsia 35 Suppl. 3 (1994) S5-S9
70. McLean M.J., Bukhari A.A., and Wamil A.W. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41 Suppl. 1 (2000) S21-S24
71. Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy. Epilepsy Res. Suppl. 11 (1996) 67-77
72. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 54 (1998) 369-415
73. Micheva K.D., Taylor C.P., and Smith S.J. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol. Pharmacol. 70 (2006) 467-476
74. Mimaki T., Suzuki Y., Tagawa T., Tanaka J., Itoh N., and Yabuuchi H. [3H]Zonisamide binding in rat brain. Jpn. J. Psychiatry Neurol. 42 3 (1988) 640-642
75. Mimaki T., Suzuki Y., Tagawa T., Karasawa T., and Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med. J. Osaka Univ. 39 (1990) 13-17
76. Ng G.Y., Bertrand S., Sullivan R., Ethier N., Wang J., Yergey J., Belley M., Trimble L., Bateman K., Alder L., Smith A., McKernan R., et al. Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol. Pharmacol. 59 (2001) 144-152
77. Niespodziany I., Klitgaard H., and Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. 306 (2001) 5-8
78. Nieto-Barrera M. Characteristics and indications of topiramate. Rev. Neurol. 35 Suppl. 1 (2002) S88-S95
79. Noyer M., Gillard M., Matagne A., Henichart J.P., and Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
80. Olsen R.W. Phenobarbital and other barbiturates: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 489-495
81. Parker D.A., Ong J., Marino V., and Kerr D.I. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur. J. Pharmacol. 495 (2004) 137-143
82. Pellock J.M., and Brodie M.J. Felbamate: 1997 update. Epilepsia 38 (1997) 1261-1264
83. Pellock J.M., Perhach J.L., and Sofia R.D. Felbamate. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 301-318
84. Petroff O.A.C., Rothman D.L., Behar K.L., Lamoureax D., and Mattson R.H. Gabapentin increases brain gama-aminobutyric acid levels in patients with epilepsy [abstract]. Ann. Neurol. 38 (1995) 295-296 Abstract M46
85. Pfizer. Lyrica (pregabalin) package insert (2006), Pfizer Inc., New York, NY
86. Piredda S.G., Woodhead J.H., and Swinyard E.A. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J. Pharmacol. Exp. Ther. 232 (1985) 741-745
87. Pisani A., Stefani A., Siniscalchi A., Mercuri N.B., Bernardi G., and Calabresi P. Electrophysiological actions of felbamate on rat striatal neurones. Br. J. Pharmacol. 116 (1995) 2053-2061
88. Putnam T.J., and Merritt H.H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85 (1937) 525-526
89. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: Are there common or different sites of action?. Eur. J. Pharmacol. 94 (1983) 341-344
90. Reinikainen K.J., Keranen T., Halonen T., Komulainen H., and Riekkinen P.J. Comparison of oxcarbazepine and carbamazepine: A double-blind study. Epilepsy Res. 1 (1987) 284-289
91. Rekling J.C., Jahnsen H., and Mosfeldt Laursen A. The effect of two lipophilic gamma-aminobutyric acid uptake blockers in CA1 of the rat hippocampal slice. Br. J. Pharmacol. 99 (1990) 103-106
92. Reynolds E.H., Chanarin I., Milner G., and Matthews D.M. Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms. Epilepsia 7 (1966) 261-270
93. Rho J.M., and Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 40 (1999) 1471-1483
94. Rho J.M., Donevan S.D., and Rogawski M.A. Mechanism of action of the anticonvulsant felbamate: Opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann. Neurol. 35 (1994) 229-234
95. Riddall D.R., Clackers M., and Leach M.J. Correlation of inhibition of veratrine evoked [14C] guanidine uptake with inhibition of veratrine evoked release of glutamate by lamotrigine and its analogues [abstract]. Can. J. Neurol. Sci. 20 Suppl. 4 (1993) S181 Abstract 6-11-17
96. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., and Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 136 (2002) 659-672
97. Rock D.M., Macdonald R.L., and Taylor C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3 (1989) 138-143
98. Roepstorff A., and Lambert J.D. Comparison of the effect of the GABA uptake blockers, tiagabine and nipecotic acid, on inhibitory synaptic efficacy in hippocampal CA1 neurones. Neurosci. Lett. 146 (1992) 131-134
99. Rogawski M.A. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 68 (2006) 22-28
100. Rogawski M.A., and Porter R.J. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42 (1990) 223-286
101. Rogers C.J., Twyman R.E., and Macdonald R.L. Benzodiazepine and beta-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J. Physiol. 475 (1994) 69-82
102. Sander J.W., and Patsalos P.N. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. 13 (1992) 89-92
103. Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 413 (1987) 185-188
104. Schmidt B. Potential antiepileptic drugs: Gabapentin. In: Levy R., Mattson R., Meldrum B., Penry J.K., and Dreifuss F.E. (Eds). "Antiepileptic Drugs". 3rd ed. (1989), Raven Press, New York 925-935
105. Schmutz M., Ferrat T., Heckendorn R., Jeker A., Portet C., and Olpe H.R. GP 47779, the main human metabolite of oxcarbazepine (Trileptal), and both enantiomers have equal anticonvulsant activity [abstract]. Epilepsia 34 Suppl. 2 (1993) 122
106. Schwarz J.R., and Grigat G. Phenytoin and carbamazepine: Potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 30 (1989) 286-294
107. Seino M., Naruto S., Ito T., and Miyazaki H. Other antiepileptic drugs. Zonisamide. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). "Antiepileptic Drugs". 4th ed. (1995), Raven Press Ltd., New York 1011-1023
108. Severt L., Coulter D.A., Sombati S., and DeLorenzo R.J. Topiramate selectively blocks kainate currents in cultured hippocampal neurons [abstract]. Epilepsia 36 Suppl. 4 (1995) 38 Abstract 2.16
109. Shank R.P., Gardocki J.F., Vaught J.L., Davis C.B., Schupsky J.J., Raffa R.B., Dodgson S.J., Nortey S.O., and Maryanoff B.E. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35 (1994) 450-460
110. Shank R.P., Gardocki J.F., Streeter A.J., and Maryanoff B.E. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 Suppl. 1 (2000) S3-S9
111. Simeone T.A., McClellan A.M.L., Twyman R.E., and White H.S. Direct activation of the recombinant α4β3γ2S GABAA receptor by the novel anticonvulsant topiramate. Soc. Neurosci. Abstr. 26 (2000) 631
112. Simeone T.A., Wilcox K.S., and White H.S. Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology 50 (2006) 845-857
113. Skradski S., and White H.S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41 Suppl. 1 (2000) S45-S47
114. Sofia R.D. Felbamate. Mechanisms of action. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). "Antiepileptic Drugs". 4th ed. (1995), Raven Press Ltd., New York 791-797
115. Stefani A., Pisani A., De Murtas M., Mercuri N.B., Marciani M.G., and Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36 (1995) 997-1002
116. Stefani A., Spadoni F., Siniscalchi A., and Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: Functional implications. Eur. J. Pharmacol. 307 (1996) 113-116
117. Stefani A., Spadoni F., and Bernardi G. Voltage-activated calcium channels: Targets of antiepileptic drug therapy?. Epilepsia 38 (1997) 959-965
118. Stefani A., Spadoni F., and Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37 (1998) 83-91
119. Stringer J.L., and Lorenzo N. The reduction in paired-pulse inhibition in the rat hippocampus by gabapentin is independent of GABA(B) receptor activation. Epilepsy Res. 33 (1999) 169-176
120. Study R.E., and Barker J.L. Diazepam and (-)-pentobarbital: Fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc. Natl. Acad. Sci. USA 78 (1981) 7180-7184
121. Subramaniam S., Rho J.M., Penix L., Donevan S.D., Fielding R.P., and Rogawski M.A. Felbamate block of the N-methyl-D-aspartate receptor. J. Pharmacol. Exp. Ther. 273 (1995) 878-886
122. Suman-Chauhan N., Webdale L., Hill D.R., and Woodruff G.N. Characterisation of [3H]gabapentin binding to a novel site in rat brain: Homogenate binding studies. Eur. J. Pharmacol. 244 (1993) 293-301
123. Suzdak P.D., and Jansen J.A. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36 (1995) 612-626
124. Suzuki S., Kawakami K., Nishimura S., Watanabe Y., Yagi K., Seino M., and Miyamoto K. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12 (1992) 21-27
125. Swinyard E.A., Sofia R.D., and Kupferberg H.J. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 27 (1986) 27-34
126. Taglialatela M., Ongini E., Brown A.M., Di Renzo G., and Annunziato L. Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain. Eur. J. Pharmacol. 316 (1996) 373-377
127. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 228 (1999) 960-968
128. Taylor C.P. Gabapentin: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 321-334
129. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., and Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29 (1998) 233-249
130. Thompson S.M., and Gahwiler B.H. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J. Neurophysiol. 67 (1992) 1698-1701
131. Thurlow R.J., Brown J.P., Gee N.S., Hill D.R., and Woodruff G.N. [3H]gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur. J. Pharmacol. 247 (1993) 341-345
132. Ticku M.K., Kamatchi G.L., and Sofia R.D. Effect of anticonvulsant felbamate on GABAA receptor system. Epilepsia 32 (1991) 389-391
133. Ticku M.K., Kulkarni S.K., and Mehta A.K. Modulatory role of GABA receptor subtypes and glutamate receptors in the anticonvulsant effect of barbiturates. Epilepsy Res. Suppl. 8 (1992) 57-62
134. Tomaselli G.F., Marban E., and Yellen G. Sodium channels from human brain RNA expressed in Xenopus oocytes. Basic electrophysiologic characteristics and their modification by diphenylhydantoin. J. Clin. Invest. 83 (1989) 1724-1732
135. Twyman R.E., Rogers C.J., and Macdonald R.L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann. Neurol. 25 (1989) 213-220
136. Van den Berg R.J., Kok P., and Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp. Brain Res. 93 (1993) 279-287
137. VanDongen A.M., VanErp M.G., and Voskuyl R.A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 27 (1986) 177-182
138. Vartanian M.G., Radulovic L.L., Kinsora J.J., Serpa K.A., Vergnes M., Bertram E., and Taylor C.P. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68 (2006) 189-205
139. - channels recorded from membrane patches of neonatal rat cortical neurons in culture. J. Pharmacol. Exp. Ther. 243 (1987) 1195-1201
140. Wakamori M., Kaneda M., Oyama Y., and Akaike N. Effects of chlordiazepoxide, chlorpromazine, diazepam, diphenylhydantoin, flunitrazepam and haloperidol on the voltage-dependent sodium current of isolated mammalian brain neurons. Brain Res. 494 (1989) 374-378
141. Wallis R.A., and Panizzon K.L. Glycine reversal of felbamate hypoxic protection. Neuroreport 4 (1993) 951-954
142. Wallis R.A., and Panizzon K.L. Felbamate neuroprotection against CA1 traumatic neuronal injury. Eur. J. Pharmacol. 294 (1995) 475-482
143. Wamil A.W. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture [abstract]. Epilepsia 32 Suppl. 3 (1991) 65
144. Wamil A.W., and McLean M.J. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res. 17 (1994) 1-11
145. Wamsley J.K., Sofia R.D., Faull R.L., Narang N., Ary T., and McCabe R.T. Interaction of felbamate with [3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortem brain. Exp. Neurol. 129 (1994) 244-250
146. Welty D.F., Schielke G.P., Vartanian M.G., and Taylor C.P. Gabapentin anticonvulsant action in rats: Disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res. 16 (1993) 175-181
147. White H.S. Mechanisms of antiepileptic drugs. In: Porter R., and Chadwick D. (Eds). "Epilepsies II" (1997), Butterworth-Heinemann, Boston 1-30
148. White H.S. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 40 Suppl. 5 (1999) S2-S10
149. White H.S. Topiramate: Mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). "Antiepileptic Drugs". 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 719-726
150. White H.S., Wolf H.H., Swinyard E.A., Skeen G.A., and Sofia R.D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33 (1992) 564-572
151. White H.S., Brown D., Skeen G.A., Wolf H.H., and Twyman R.E. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia 36 Suppl. 3 (1995) S39-S40
152. White H.S., Harmsworth W.L., Sofia R.D., and Wolf H.H. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res. 20 (1995) 41-48
153. White H.S., Woodhead J.H., Franklin M.R., Swinyard E.A., and Wolf H.H. General principles: Experimental selection, quantification, and evaluation of antiepileptic drugs. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). "Antiepileptic Drugs". 4th ed. (1995), Raven Press, New York 99-110
154. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., and Wolf H.H. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 28 (1997) 167-179
155. Willow M., and Catterall W.A. Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 22 (1982) 627-635
156. Willow M., Kuenzel E.A., and Catterall W.A. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25 (1984) 228-234
157. Willow M., Gonoi T., and Catterall W.A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 27 (1985) 549-558
158. Yamakura T., Sakimura K., Mishina M., and Shimoji K. The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the alpha 2 subunit. FEBS Lett. 374 (1995) 412-414
159. Zhang X., Velumian A.A., Jones O.T., and Carlen P.L. Topiramate reduces high-voltage activated Ca2+ currents in CA1 pyramidal neurons in vitro [abstract]. Epilepsia 39 Suppl. 6 (1998) 44
160. Zhang X., Velumian A.A., Jones O.T., and Carlen P.L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41 Suppl. 1 (2000) S52-S60
161. Zona C., and Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp. Brain Res. 81 (1990) 313-317
162. Zona C., Ciotti M.T., and Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. 231 (1997) 123-126